Trial Profile
TBCRC 023: A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib Pus Trastuzumab, With or Without Endocrine Therapy for 12 Weeks vs. 24 Weeks in Patients With HER2 Overexpressing Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 May 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Trastuzumab (Primary) ; Letrozole
- Indications Advanced breast cancer; Carcinoma; Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms HELEX
- 17 May 2023 Results (TBCRC023 and PAMELA studies) hypothesizing that a multiparameter classifier can identify patients with HER2 "addicted" tumors who may benefit from a chemotherapy-sparing strategy published in the Clinical Cancer Research
- 15 May 2022 Planned End Date changed from 1 Jan 2022 to 1 Jan 2024.
- 16 Jul 2020 Planned End Date changed from 1 Jan 2020 to 1 Jan 2022.